JW Pharmaceutical Corporation (001065.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	820.4B	774.8B	719.4B	748.5B	684.4B
Cost of Revenue	432.6B	416.0B	395.9B	412.9B	396.4B
Gross Profit	388.2B	359.3B	323.5B	335.7B	288.0B
Operating Expenses
R&D Expense	34.8B	45.4B	36.2B	33.7B	33.7B
SG&A Expense	191.8B	167.1B	157.9B	152.6B	126.7B
General & Admin Expense	142.7B	131.0B	120.8B	116.8B	91.2B
Selling & Marketing Expense	36.6B	36.1B	37.1B	35.9B	35.5B
Other Expenses	62.5B	58.9B	46.9B	48.9B	64.7B
Total Operating Expenses	273.8B	271.4B	241.0B	235.2B	225.2B
Cost and Expenses	706.5B	687.4B	636.9B	651.9B	621.6B
Operating Income (EBIT)	114.4B	87.9B	82.5B	96.6B	63.0B
Non-Operating
Interest Income	8.4B	3.2B	4.9B	5.9B	5.3B
Interest Expense	7.7B	4.4B	10.0B	12.6B	9.4B
Net Interest Income	774.9M	(1.2B)	(5.2B)	(6.7B)	(4.1B)
Other Non-Op Income/Expense	903.7M	959.3M	(68.6M)	(41.8B)	(17.6B)
Non-Operating Income (excl Interest)	1.2B	—	(10.0B)	30.0B	6.7B
EBT (Pre-Tax Income)	115.3B	88.8B	82.4B	54.8B	45.4B
Income Tax Expense	14.0B	27.3B	17.4B	16.4B	15.5B
Bottom Line
Net Income	101.3B	61.7B	65.0B	37.0B	31.9B
Earnings from Cont. Ops	101.3B	61.7B	65.0B	38.4B	29.9B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	98.4B	61.7B	61.7B	35.1B	30.3B
Per Share
Basic EPS	₩4,193	₩2,535	₩2,644	₩1,426	₩1,267
Diluted EPS	₩4,193	₩2,535	₩2,644	₩1,426	₩1,267
Revenue Per Share	₩34,720	₩32,093	₩30,841	₩30,422	₩28,608
Shares
Basic Shares Outstanding	23.6M	24.1M	23.3M	24.6M	23.9M
Diluted Shares Outstanding	23.6M	24.1M	23.3M	24.6M	23.9M
Profitability Metrics
EBITDA	125.8B	106.6B	110.2B	89.2B	73.5B
D&A	19.5B	18.7B	19.1B	22.4B	17.2B
EBIT	106.3B	87.9B	91.1B	66.8B	56.3B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026